A Phase 1 Varegacestat Hepatic Impairment Study

Description

This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.

Conditions

Healthy Volunteer, Hepatic Impairment (HI)

Talk to us

Study Overview

On this page

Study Details

Study overview

This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Varegacestat in Participants with or Without Hepatic Impairment

A Phase 1 Varegacestat Hepatic Impairment Study

Condition
Healthy Volunteer
Intervention / Treatment

-

Contacts and Locations

Orlando

Orlando Clinical Research Center, Orlando, Florida, United States, 32809

San Antonio

The Texas Liver Institute, San Antonio, Texas, United States, 78215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 84 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    Yes

    Collaborators and Investigators

    Immunome, Inc.,

    Study Record Dates

    2025-12